{"id":"https://openalex.org/W2891635705","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e18619","title":"Affordability of drug treatment in advanced non-small cell lung cancer.","display_name":"Affordability of drug treatment in advanced non-small cell lung cancer.","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2891635705","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e18619","mag":"2891635705"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.e18619","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e18619","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.e18619","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000666287","display_name":"Yi-Ting Chou","orcid":"https://orcid.org/0000-0002-4922-5353","observed_orcids":["https://orcid.org/0000-0002-4922-5353"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yi-Ting Chou","raw_affiliation_strings":["Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056882162","display_name":"Jennifer Elston Lafata","orcid":"https://orcid.org/0000-0002-8550-6195","observed_orcids":["https://orcid.org/0000-0002-8550-6195"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Elston Lafata","raw_affiliation_strings":["Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043419293","display_name":"Joel F. Farley","orcid":"https://orcid.org/0000-0002-5196-5238","observed_orcids":["https://orcid.org/0000-0002-5196-5238"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]},{"id":"https://openalex.org/I2800403580","display_name":"University of Minnesota System","ror":"https://ror.org/03grvy078","country_code":"US","type":"education","lineage":["https://openalex.org/I2800403580"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel Farley","raw_affiliation_strings":["Department of Pharmaceutical Care &amp; Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Care &amp; Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN;","institution_ids":["https://openalex.org/I130238516","https://openalex.org/I2800403580"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tom Stinchcombe","raw_affiliation_strings":["Department of Medicine, Duke University School of Medicine; Duke Cancer Institute, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Duke University School of Medicine; Duke Cancer Institute, Durham, NC;","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113850219","display_name":"Amber Proctor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amber Proctor","raw_affiliation_strings":["Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041418355","display_name":"Stacie B. Dusetzina","orcid":"https://orcid.org/0000-0002-3907-9196","observed_orcids":["https://orcid.org/0000-0002-3907-9196"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacie Dusetzina","raw_affiliation_strings":["Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN;","institution_ids":["https://openalex.org/I901861585"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"e18619","last_page":"e18619"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.9067000150680542,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.9067000150680542,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.08820000290870667,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-affordability","display_name":"drug affordability","score":0.8180000185966492},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.9750000238418579},{"id":"https://openalex.org/keywords/medicare-part-d","display_name":"Medicare Part D","score":0.593999981880188},{"id":"https://openalex.org/keywords/medicare-part-b","display_name":"Medicare Part B","score":0.9959999918937683},{"id":"https://openalex.org/keywords/prescription-drug-prices","display_name":"prescription drug prices","score":0.8339999914169312},{"id":"https://openalex.org/keywords/out-of-pocket-costs","display_name":"out-of-pocket costs","score":0.9319999814033508},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6520000100135803},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.968999981880188},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.8029999732971191},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.9810000061988831},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.4690000116825104},{"id":"https://openalex.org/keywords/value-based-pricing","display_name":"value-based pricing","score":0.7450000047683716},{"id":"https://openalex.org/keywords/drug-price-regulation","display_name":"drug price regulation","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8660733699798584},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6866698861122131},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.6056432723999023},{"id":"https://openalex.org/C2778858636","wikidata":"https://www.wikidata.org/wiki/Q1643563","display_name":"Prescription drug","level":3,"score":0.602203905582428},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.583853006362915},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5426751375198364},{"id":"https://openalex.org/C2910862244","wikidata":"https://www.wikidata.org/wiki/Q7240896","display_name":"Drug prices","level":2,"score":0.5347439646720886},{"id":"https://openalex.org/C2776534028","wikidata":"https://www.wikidata.org/wiki/Q1141363","display_name":"Medicaid","level":3,"score":0.49177196621894836},{"id":"https://openalex.org/C3020340455","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Cancer drugs","level":3,"score":0.46986258029937744},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.41283735632896423},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3656471371650696},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.321353942155838},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.30497217178344727},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.297371506690979},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.27832210063934326},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.22231310606002808},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.e18619","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e18619","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.e18619","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6924987283","https://openalex.org/W4407631446","https://openalex.org/W4388197778","https://openalex.org/W2928660898","https://openalex.org/W2765547073","https://openalex.org/W4206897037","https://openalex.org/W7169803739","https://openalex.org/W4399699876","https://openalex.org/W2898579231","https://openalex.org/W2156800377"],"abstract_inverted_index":{"e18619":[0],"Background:":[1],"Novel":[2],"treatments":[3],"have":[4,189],"been":[5],"approved":[6],"for":[7,51,86,95,114,124,141,155,222,265,272,286],"advanced":[8,49,287],"non-small":[9],"cell":[10],"lung":[11],"cancer":[12],"(NSCLC)":[13],"to":[14,26,40,42,91,165,181,260,282,301,312,317],"improve":[15],"patient":[16,255,320],"outcomes;":[17],"however,":[18],"their":[19,27],"high":[20,227],"costs":[21,123],"could":[22],"pose":[23],"significant":[24],"barriers":[25],"widespread":[28],"use.":[29],"We":[30,70,108],"examined":[31],"changes":[32],"in":[33,36,48,134,163,167],"drug-specific":[34],"prices":[35,113,149,188],"Medicare":[37,87],"from":[38,83,161,262],"2010":[39,164],"2017":[41,135],"provide":[43,309],"insights":[44],"into":[45],"drug":[46,65,112,116,126,187,269,296,303],"affordability":[47,279],"NSCLC":[50,288],"products":[52,204],"covered":[53,157,171],"on":[54,61,228],"the":[55,62,72,78,84,128,195],"medical":[56],"benefit":[57,66,132],"(Part":[58,67],"B)":[59],"and":[60,77,100,117,119,232,245,270,294,308],"outpatient":[63],"prescription":[64],"D).":[68,251],"Methods:":[69],"used":[71],"Prescription":[73],"Drug":[74],"Pricing":[75],"file":[76],"Average":[79],"Sales":[80],"Price":[81],"data":[82],"Centers":[85],"&":[88],"Medicaid":[89],"Services":[90],"obtain":[92],"price":[93,178,304],"information":[94],"Part":[96,101,130,142,159,173,185,230,233,238,243,250,267,274],"D":[97,131,174,275],"(oral":[98],"drugs)":[99,105],"B":[102,186,231,268],"(mostly":[103],"infused":[104],"drugs,":[106],"respectively.":[107],"identified":[109],"median":[110],"point-of-sale":[111],"each":[115,125],"year":[118],"calculated":[120],"expected":[121,254],"out-of-pocket":[122,256],"using":[127],"standard":[129],"design":[133],"or":[136,211,219],"assuming":[137],"a":[138,266,273],"20%":[139],"coinsurance":[140],"B.":[143],"Results:":[144],"Over":[145,194],"time":[146],"higher":[147],"entry":[148],"at":[150],"FDA":[151],"approval":[152],"were":[153,200,217,226],"observed":[154],"drugs":[156,170],"under":[158,172],"D,":[160],"$2,293/month":[162],"$14,079/month":[166],"2017.":[168],"Older":[169],"also":[175],"experienced":[176],"considerable":[177],"hikes":[179],"(up":[180],"244%).":[182],"In":[183,252],"contrast,":[184],"remained":[190],"stable":[191],"over":[192],"time.":[193],"study":[196],"period":[197],"traditional":[198],"chemotherapies":[199],"priced":[201],"below":[202],"$100/month;":[203],"with":[205],"new":[206],"formulations":[207],"(e.g.,":[208,215,305],"albumin-bound":[209],"paclitaxel)":[210],"newer":[212],"chemotherapy":[213],"agents":[214],"pemetrexed)":[216],"$8,000/month":[218,240],"more.":[220],"Prices":[221],"novel":[223],"targeted":[224],"therapies":[225],"both":[229],"D;":[234],">":[235,246],"$10,000/month":[236],"(immunotherapy,":[237],"B),":[239],"(EGFR-targeted":[241],"agents,":[242],"D),":[244],"$13,000/month":[247],"(ALK-targeted":[248],"therapy,":[249],"2017,":[253],"spending":[257],"was":[258],"estimated":[259],"range":[261],"<":[263],"$40-$3,000/month":[264],"$1,800-$3,500/month":[271],"drug.":[276],"Conclusions:":[277],"Treatment":[278],"is":[280,315],"likely":[281],"present":[283],"continued":[284],"challenges":[285],"patients":[289],"given":[290],"current":[291],"plan":[292],"benefits":[293],"ever-increasing":[295],"prices.":[297],"A":[298],"sustainable":[299],"mechanism":[300],"control/monitor":[302],"value-based":[306],"pricing)":[307],"financial":[310],"access":[311],"these":[313],"medications":[314],"needed":[316],"ensure":[318],"optimal":[319],"outcomes.":[321]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-09-27T00:00:00"}